ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

As the treatment landscape for IgA nephropathy grows increasingly complex, new data presented at the World Congress of Nephrology 2026 in Yokohama, Japan, are beginning to clarify how emerging therapies may work together.

In this episode of Kidney Compass, hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, sat down with Hiddo Heerspink, PhD, PharmD, to discuss the phase 2 ASSIST trial, which evaluated the efficacy and safety of atrasentan in combination with SGLT2 inhibitors.

0:00:00 – Episode introduction & trial focus
0:00:40 – Rationale & design of ASSIST
0:02:04 – Detailed crossover structure
0:02:59 – Inclusion of lower proteinuria patients
0:04:20 – Relationship to ALIGN trial
0:05:42 – Main efficacy & safety findings
0:08:43 – Role of crossover studies & individual response
0:10:37 – Future sequencing of therapies

https://www.hcplive.com/view/kidney-compass-assist-trial-shows-atrasentan-benefit-on-top-of-sglt2-inhibitors